BLISS GVS PHARMA LTD. - 506197 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Vibha Gagan Sharma & PACs BLISS GVS PHARMA LTD. - 506197 - Intimation About Closure Of US FDA Inspection At Plot 11 Of The Company
Further to the information dated March 18, 2023, we hereby notify that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) at the Company''s manufacturing unit at Plot No. 11, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, Maharashtra from Monday, March 13, 2023, to Friday, March 17, 2023. Pursuant to above inspection by the United States Food and Drug Administration (US FDA), the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection through which the US FDA agency assigned the inspection classification of the facility as 'Voluntary Action Indicated (VAI)'. Based on this inspection and the US FDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP). Kindly take the above information on record. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on June 02, 2023, has approved the allotment of 44,500 equity shares of face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 ('Bliss GVS ESOP-2019'). BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith the Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2023. This is for your information and record. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of the newspaper advertisement of the Audited Financial Results of the Company for the quarter and year ended March 31, 2023, published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshakti' a Regional Daily, on May 13, 2023. BLISS GVS PHARMA LTD. - 506197 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company BLISS GVS PHARMA LTD. 2 CIN NO. L24230MH1984PLC034771 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-2023; FY 2023-2024 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2022-2023; FY 2021-2022 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Aditi BhattDesignation :-Company Secretary Name of the Chief Financial Officer :- Deepak Sawant Designation : -Chief Financial Officer Date: 15/05/2023 BLISS GVS PHARMA LTD. - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019
Pursuant to Regulation 30 of Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that the Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ('the Company') in its meeting held yesterday i.e. May 11, 2023, has granted 11,55,000 Employee Stock Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 to the eligible employees of the Company. BLISS GVS PHARMA LTD. - 506197 - Intimation Of Book Closure In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Section 91 of the Companies Act, 2013 ('Act'') and applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with our intimation submitted to you w.r.t. Final Dividend on May 11, 2023, the Register of Members and Share Transfer Books of the Company will remain closed from Thursday, July 13, 2023 to Wednesday, July 19, 2023 (both the days inclusive) for taking on record of the members of the Company for the purpose of holding 38th Annual General Meeting of the Company which will be held on Wednesday, July 19, 2023 for the financial year ended March 31, 2023 and payment of Final Dividend for the financial year ended March 31, 2023. BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith a disclosure of Related Party Transactions in the specified format for the half year ended March 31, 2023.